- Duloxetine, a Selective Noradrenaline Reuptake Inhibitor, Increased Plasma Levels of 3-Methoxy-4-hydroxyphenylglycol but Not Homovanillic Acid in Patients with Major Depressive Disorder
-
Atake K, Yoshimura , Hori H, Katsuki A, Ikenouchi-Sugita A, Umene-Nakano W, Nakamura J
- KMID: 2171127
- Clin Psychopharmacol Neurosci.
- 2014 Apr;12(1):37-40.
OBJECTIVE: We investigated the effects of duloxetine on the plasma levels of catecholamine metabolites and serum brain-derived neurotrophic factor (BDNF) in 64 patients with major depressive disorder (MDD). METHODS: Major depressive... -
- CITED
-
- Close
- SHARE
-
- Close
- Follow-up Study on Electroconvulsive Therapy in Treatment-resistant Depressed Patients after Remission: A Chart Review
-
Tokutsu Y, Umene-Nakano W, Shinkai T, Yoshimura , Okamoto T, Katsuki A, Hori H, Ikenouchi-Sugita A, Hayashi K, Atake K, Nakamura J
- KMID: 2171195
- Clin Psychopharmacol Neurosci.
- 2013 Apr;11(1):34-38.
OBJECTIVE: Electroconvulsive therapy (ECT) has proven to be effective in treatment-resistant depression (TRD). In recent reports, 70% to 90% of patients with TRD responded to ECT. However, post-ECT relapse is... -
- CITED
-
- Close
- SHARE
-
- Close
- Serum Levels of Brain-Derived Neurotrophic Factor at 4 Weeks and Response to Treatment with SSRIs
-
Yoshimura , Kishi T, Hori H, Katsuki A, Sugita-Ikenouchi A, Umene-Nakano W, Atake K, Iwata N, Nakamura J
- KMID: 2316335
- Psychiatry Investig.
- 2014 Jan;11(1):84-88.
OBJECTIVE: It is important to predict a response to an antidepressant in early time after starting the antidepressant. We previously reported that serum brain-derived neurotrophic factor (BDNF) levels in responders... -
- CITED
-
- Close
- SHARE
-
- Close
